Dr. Axel Grothey on Differences Between CORRECT and CONCUR Studies in mCRC

Axel Grothey, MD,
Published: Thursday, Jul 16, 2015



Axel Grothey, MD, department of Oncology, Mayo Clinic, Rochester, MN, discusses the differences between the CORRECT and CONCUR trials, which both looked at regorafenib for previously treated metastatic colorectal cancer (mCRC).

In the international phase III CORRECT trial, a survival benefit was observed with regorafenib over placebo in mCRC, gaining FDA approval for the drug.

The CORRECT trial included 760 patients from North America, Europe, Australia, and Asia. However only four Chinese patients were enrolled in the trial due to rapid accruement, said Grothey.

The CONCUR trial, which was also a phase III trial, was conducted to confirm the effectiveness of regorafenib in Asian mCRC patients and included 204 patients from Asian countries, including 172 Chinese patients. The patients in this trial were also not as heavily pre-treated in CONCUR as in CORRECT, resulting in an even more significant survival benefit.



Axel Grothey, MD, department of Oncology, Mayo Clinic, Rochester, MN, discusses the differences between the CORRECT and CONCUR trials, which both looked at regorafenib for previously treated metastatic colorectal cancer (mCRC).

In the international phase III CORRECT trial, a survival benefit was observed with regorafenib over placebo in mCRC, gaining FDA approval for the drug.

The CORRECT trial included 760 patients from North America, Europe, Australia, and Asia. However only four Chinese patients were enrolled in the trial due to rapid accruement, said Grothey.

The CONCUR trial, which was also a phase III trial, was conducted to confirm the effectiveness of regorafenib in Asian mCRC patients and included 204 patients from Asian countries, including 172 Chinese patients. The patients in this trial were also not as heavily pre-treated in CONCUR as in CORRECT, resulting in an even more significant survival benefit.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x